JPRN-jRCT2080224791已完成1 期
A Phase Ib Study of YHI-1702 (duvelisib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Diagnosis of active CLL or SLL
- •- Disease that has progressed during or relapsed after at least one previous CLL/SLL therapy
- •- Measurable disease > 1.5 cm
- •- ECOG PS of 0 or 1
- •- Presence of adequate organ and bone-marrow functions
排除标准
- •- History of Richter's transformation or prolymphocytic leukemia
- •- Known central nervous system lymphoma or leukemia
- •- Prior exposure to a PI3K inhibitor
- •- Unstable or severe uncontrolled medical condition
- •- Pregnant or lactating women
研究者
相似试验
已完成
2 期
A Phase II Study of YHI-1702JPRN-jRCT2071210133Hiroki Kageyama21
已完成
2 期
A Phase II Study of YHI-1702Follicular lymphomaJPRN-jRCT2031210529Suzuki Kenta36
未知
1 期
Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapyPatients with non-small cell lung cancer who have received platinum-based chemotherapyJPRN-jRCT2080222077Yakult Honsha Co., Ltd.118
进行中（未招募）
1 期
A study of JNJ-75276617 in combination with acute myeloid leukemia-directed therapiesCancerAcute myeloid leukemiaISRCTN12278036Janssen Pharmaceutica NV150
未知
1 期
A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapyJPRN-jRCT2080222078Yakult Honsha Co., Ltd.164